The APE1/REF-1 and the hallmarks of cancer.
Priscyanne Barreto SiqueiraMariana Moreno de Sousa RodriguesÍsis Salviano Soares de AmorimThayssa Gomes FariasMatheus da Silva OliveiraJuliana Alves RodriguesAdenilson de Souza da FonsecaAndré Luiz MencalhaPublished in: Molecular biology reports (2024)
APE1/REF-1 (apurinic/apyrimidinic endonuclease 1 / redox factor-1) is a protein with two domains, with endonuclease function and redox activity. Its main activity described is acting in DNA repair by base excision repair (BER) pathway, which restores DNA damage caused by oxidation, alkylation, and single-strand breaks. In contrast, the APE1 redox domain is responsible for regulating transcription factors, such as AP-1 (activating protein-1), NF-κB (Nuclear Factor kappa B), HIF-1α (Hypoxia-inducible factor 1-alpha), and STAT3 (Signal Transducers and Activators of Transcription 3). These factors are involved in physiological cellular processes, such as cell growth, inflammation, and angiogenesis, as well as in cancer. In human malignant tumors, APE1 overexpression is associated with lung, colon, ovaries, prostate, and breast cancer progression, more aggressive tumor phenotypes, and worse prognosis. In this review, we explore APE1 and its domain's role in cancer development processes, highlighting the role of APE1 in the hallmarks of cancer. We reviewed original articles and reviews from Pubmed related to APE1 and cancer and found that both domains of APE1/REF-1, but mainly its redox activity, are essential to cancer cells. This protein is often overexpressed in cancer, and its expression and activity are correlated to processes such as proliferation, invasion, inflammation, angiogenesis, and resistance to cell death. Therefore, APE1 participates in essential processes of cancer development. Then, the activity of APE1/REF-1 in these hallmarks suggests that targeting this protein could be a good therapeutic approach.
Keyphrases
- papillary thyroid
- dna repair
- dna damage
- nuclear factor
- squamous cell
- oxidative stress
- transcription factor
- cell death
- prostate cancer
- randomized controlled trial
- magnetic resonance imaging
- poor prognosis
- childhood cancer
- inflammatory response
- cell proliferation
- drug delivery
- long non coding rna
- dna binding
- induced pluripotent stem cells
- dna damage response
- contrast enhanced